The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving

Journal of Medical Economics
Natalie C EdwardsJohn Fastenau

Abstract

To identify, estimate, and compare 'real world' costs and outcomes associated with paliperidone palmitate compared with branded oral atypical anti-psychotics, and to estimate the threshold rate of oral atypical adherence at which paliperidone palmitate is cost saving. Decision analytic modeling techniques developed by Glazer and Ereshefsky have previously been used to estimate the cost-effectiveness of depot haloperidol, LAI risperidone, and, more recently, LAI olanzapine. This study used those same techniques, along with updated comparative published clinical data, to evaluate paliperidone palmitate. Adherence rates were based on strict Medication Event Monitoring System (MEMS) criteria. The evaluation was conducted from the perspective of US healthcare payers. Paliperidone palmitate patients had fewer mean annual days of relapse (8.7 days; 6.0 requiring hospitalization, 2.7 not requiring hospitalization vs 17.8 days; 12.4 requiring hospitalization, 5.4 not requiring hospitalization), and lower annual total cost ($20,995) compared to oral atypicals (mean $22,481). Because paliperidone palmitate was both more effective and less costly, it is considered economically dominant. Paliperidone palmitate saved costs when the rate of a...Continue Reading

References

Mar 1, 1977·Archives of General Psychiatry·G E Hogarty, R F Ulrich
May 1, 1994·Drugs·J M DavisL ] Metalon L [corrected to Matalon
May 9, 1998·Psychiatric Services : a Journal of the American Psychiatric Association·J A Cramer, R Rosenheck
Feb 2, 2000·Psychiatric Services : a Journal of the American Psychiatric Association·M OlfsonP J Weiden
Mar 21, 2001·Biological Psychiatry·J LiebermanR Bilder
Oct 3, 2001·The British Journal of Psychiatry : the Journal of Mental Science·C E AdamsA S David
Mar 3, 2004·The American Journal of Psychiatry·Delbert G RobinsonRobert M Bilder
Apr 20, 2005·PharmacoEconomics·Natalie C EdwardsRonald J Diamond
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Nov 17, 2006·The Journal of Clinical Psychiatry·Jeffrey A Lieberman
Apr 7, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·William M Glazer
Apr 7, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·Lizheng ShiStephen R Marder
Feb 2, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Joyce A CramerPeter K Wong
Jul 17, 2008·Current Psychiatry Reports·William M Glazer, Mathew J Byerly
Oct 29, 2008·Current Medical Research and Opinion·Natalie C EdwardsRiad Dirani
Apr 9, 2009·Cost Effectiveness and Resource Allocation : C/E·Nicolas M FuriakSteven D Culler
May 28, 2010·The British Journal of Psychiatry. Supplement·John M Kane, Carlos Garcia-Ribera
Feb 19, 2010·Current Medical Research and Opinion·Deborah NichollJan Schadrack
May 8, 2010·CNS Spectrums·José Ramón Gutiérrez-CasaresDavid Alonso-Escolano
Nov 26, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Gahan PandinaGeorge Simpson
Jan 14, 2011·The Journal of Clinical Psychiatry·Donald C GoffOliver Freudenreich
Apr 30, 2011·The Journal of Clinical Psychiatry·Donald C GoffOliver Freudenreich
May 11, 2011·International Journal of Methods in Psychiatric Research·Martijn J KikkertAart H Schene
Jun 4, 2011·Schizophrenia Research·Vered Baloush-KleinmanMichael Poyurovsky
Jul 21, 2011·Nordic Journal of Psychiatry·Eva LindströmChristophe Sapin
Sep 22, 2011·ClinicoEconomics and Outcomes Research : CEOR·Xiaomei PengJohn M Kane

❮ Previous
Next ❯

Citations

Sep 6, 2013·Journal of Medical Economics·Thomas R Einarson, Michiel E H Hemels
Dec 15, 2012·Expert Review of Neurotherapeutics·Pierre Chue, James Chue
Feb 20, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Marie-Hélène LafeuillePatrick Lefebvre
Aug 27, 2013·Applied Health Economics and Health Policy·Jan ZeidlerStephan Heres
Aug 22, 2018·Journal of Market Access & Health Policy·Junwen ZhouMondher Toumi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here